Accessibility Menu
 
Vita Life Sciences logo

Vita Life Sciences

(ASX) VLS

Current Price$2.59
Market Cap$138.09M
Since IPO (2007)+2,550%
5 Year+133%
1 Year+43%
1 Month+4%

Vita Life Sciences Financials at a Glance

Market Cap

$138.09M

Revenue (TTM)

$172.78M

Net Income (TTM)

$19.22M

EPS (TTM)

$0.18

P/E Ratio

13.90

Dividend

$0.14

Beta (Volatility)

-0.08 (Low)

Price

$2.59

Volume

10,433

Open

$2.60

Previous Close

$2.59

Daily Range

$2.59 - $2.60

52-Week Range

$1.70 - $2.84

VLS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vita Life Sciences

Industry

Pharmaceuticals

CEO

Andrew OKeefe

Headquarters

Kirrawee, NSW 2232, AU

VLS Financials

Key Financial Metrics (TTM)

Gross Margin

61%

Operating Margin

16%

Net Income Margin

11%

Return on Equity

19%

Return on Capital

25%

Return on Assets

13%

Earnings Yield

7.19%

Dividend Yield

0.05%

Payout Ratio

58.26%

Stock Overview

Market Cap

$138.09M

Shares Outstanding

53.31M

Volume

10.43K

Short Interest

0.00%

Avg. Volume

15.04K

Financials (TTM)

Gross Profit

$56.03M

Operating Income

$14.66M

EBITDA

$15.66M

Operating Cash Flow

$16.43M

Capital Expenditure

$570.00K

Free Cash Flow

$15.86M

Cash & ST Invst.

$35.56M

Total Debt

$4.30M

Vita Life Sciences Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$47.73M

+20.9%

Gross Profit

$29.65M

+29.3%

Gross Margin

62.12%

N/A

Market Cap

$138.09M

N/A

Market Cap/Employee

$345.21K

N/A

Employees

400

N/A

Net Income

$5.59M

+9.8%

EBITDA

$7.71M

+5.2%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$31.26M

+28.9%

Accounts Receivable

$13.64M

+21.6%

Inventory

$15.08M

+35.2%

Long Term Debt

$3.82M

+2071.6%

Short Term Debt

$482.00K

+14.2%

Return on Assets

12.67%

N/A

Return on Invested Capital

25.19%

N/A

Free Cash Flow

$9.99M

+27.4%

Operating Cash Flow

$9.83M

+16.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RCE.AXRecce Pharmaceuticals Ltd
$0.48+5.49%
ACW.AXActinogen Medical Limited
$0.04+0.00%
ALC.AXAlcidion Group Limited
$0.10+0.00%
AHC.AXAustco Healthcare Limited
$0.34-1.43%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$48.96+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.45+0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$67.86-0.02%
NOKNokia
$9.55+0.01%

Questions About VLS

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.